These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
    Author: Bookman MA.
    Journal: Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378.
    Abstract:
    Although the combination of platinum and paclitaxel offers effective chemotherapy for advanced ovarian cancer, the majority of women will eventually relapse with development of drug-resistant disease. Topotecan is the most extensively studied agent currently available for management of recurrent ovarian cancer and has been approved by the FDA for that particular indication. Early use of topotecan offers an effective and tolerable strategy that can prolong the platinum-free interval and optimize subsequent retreatment with platinum.
    [Abstract] [Full Text] [Related] [New Search]